Related Experiment Video

Updated: Oct 26, 2026

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Solution structures of micelle-bound amyloid beta-(1-40) and beta-(1-42) peptides of Alzheimer's disease

H Shao1, S Jao, K Ma

  • 1Department of Chemistry, Case Western Reserve University, Cleveland, OH, 44106, USA.

Journal of Molecular Biology
|January 8, 1999
PubMed

Insights

Sodium dodecyl sulphate micelles prevent amyloid beta-peptide aggregation into neurotoxic structures. Instead, they promote alpha-helical folding, offering insights for Alzheimer's disease inhibitor design.

Area of Science:

  • Biochemistry
  • Neuroscience
  • Structural Biology

Background:

  • Amyloid beta-peptide is a key component of Alzheimer's disease plaques.
  • Two main forms exist: beta-(1-40) in cerebrovascular amyloid and beta-(1-42) in plaque cores.
  • Understanding beta-peptide aggregation is crucial for Alzheimer's research.

Purpose of the Study:

  • To investigate the structural behavior of amyloid beta-peptide in a membrane-mimicking environment.
  • To determine if sodium dodecyl sulphate (SDS) micelles can prevent the formation of neurotoxic beta-sheet structures.
  • To elucidate the three-dimensional structure of beta-(1-42) in the presence of SDS micelles.

Main Methods:

  • Nuclear Magnetic Resonance (NMR) spectroscopy, including Nuclear Overhauser Enhancement (NOE) and chemical shift analysis.
  • Utilized sodium dodecyl sulphate (SDS) micelles as a membrane-mimicking system.
  • Studied both beta-(1-40) and beta-(1-42) peptides.

Main Results:

  • SDS micelles prevented the aggregation of beta-(1-40) and beta-(1-42) into beta-pleated sheets.
  • Micelles promoted the formation of predominantly alpha-helical structures at pH 7.2.
  • NMR revealed a detailed 3D structure for beta-(1-42) with specific alpha-helical regions and a looped segment.
  • Beta-peptide was found at the micelle's lipid-water interface, not embedded in the hydrophobic core.

Conclusions:

  • SDS micelles offer a protective environment against amyloidogenic aggregation.
  • The observed alpha-helical structures may represent a non-toxic conformation of beta-peptide.
  • Findings suggest implications for beta-peptide circulation and potential therapeutic strategies for Alzheimer's disease by inhibiting alpha-helix to beta-sheet conversion.

More Related Videos

A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation06:34

A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation

Published on: March 27, 2017

Characterization of pH-Dependent Reversible Self-Assembly of Amyloid Beta 1-40-Coated Gold Colloids08:53

Characterization of pH-Dependent Reversible Self-Assembly of Amyloid Beta 1-40-Coated Gold Colloids

Published on: March 21, 2025

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...